Works matching IS 0008543X AND DT 2018 AND VI 124 AND IP 2


Results: 28
    1
    2
    3
    4
    5
    6
    9
    10
    11
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24

    Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

    Published in:
    2018
    By:
    • Fathi, Amir T.;
    • Blonquist, Traci M.;
    • Hernandez, Daniela;
    • Amrein, Philip C.;
    • Ballen, Karen K.;
    • McMasters, Malgorzata;
    • Avigan, David E.;
    • Joyce, Robin;
    • Logan, Emma K.;
    • Hobbs, Gabriela;
    • Brunner, Andrew M.;
    • Joseph, Christelle;
    • Perry, Ashley M.;
    • Burke, Meghan;
    • Behnan, Tanya;
    • Foster, Julia;
    • Bergeron, Meghan K.;
    • Moran, Jenna A.;
    • Ramos, Aura Y.;
    • Som, Tina T.
    Publication type:
    journal article
    25
    26
    27
    28